Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing

REGENXBIO expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data. Read why RGNX stock is a ...

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing ...

USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that ...